CSRHub is the world’s largest CSR (corporate social responsibility) and sustainability ratings and information database.

Novartis AG is a developer, manufacturer, and distributor of pharmaceuticals and healthcare products. The Company’s products include pharmaceuticals, vaccines and diagnostics, generic medications, over the counter drugs, animal health medicines, and CIBA vision products. Headquartered in Basel, Switzerland, the Company has operations in the Americas, Europe, Africa, Asia, and Australia.

Ticker: NVS ISIN: CH0012005267
Address: Lichtstrasse 35 , Switzerland , Basel , , 4022 Website: Novartis AG
Phone #: 41-61-3241111 CSR Web Area: SUBSCRIPTION INFO

Basic Corporate Social Responsibility (CSR) Ratings

  Overall Community Employees Environment Governance
Novartis AG 64 63 66 68 55
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 55 55 56 58 52
Switzerland
SUBSCRIPTION INFO

Percentile Rankings

Rankings are in percentile terms, compared to other companies in the same industry and country Overall Community Employees Environment Governance
Novartis AG 92% 82% 82% 83% 57%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
Switzerland
SUBSCRIPTION INFO
Special Issues:

Ratings History

Only subscribers can interact with the graph.

More CSR Rating Details

  Community Employees
Community Dev & Philanthropy Product Human Rights & Supply Chain Compensation & Benefits Diversity & Labor Rights Training, Health & Safety
Novartis AG
SUBSCRIPTION INFO
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 53 54 55 58 55 55
Switzerland
SUBSCRIPTION INFO

Environment Governance
Energy & Climate Change Environmant Policy & Reporting Resource Management Board Leadership Ethics Transparency & Reporting
Novartis AG
SUBSCRIPTION INFO
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 57 58 57 50 55 51
Switzerland
SUBSCRIPTION INFO

Percentile rankings

Rankings are in percentile terms, compared to other companies in the same industry and country Community Employees
Community Dev & Philantrophy Product Human Rights & Supply Chain Compensation & Benefits Diversity & Labor Rights Training, Health & Safety
Novartis AG 84% 70% 84% 66% 78% 93%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
Switzerland
SUBSCRIPTION INFO

Environment Governance
Energy & Climate Change Environment Policy & Reporting Resource Management Board Leadership Ethics Transparency & Reporting
Novartis AG 82% 86% 75% 49% 47% 79%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
Switzerland
SUBSCRIPTION INFO

0 Special Issues Affect This Company (see a list of issues here)

# of Sources
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
Overall database
Switzerland
SUBSCRIPTION INFO

CSRHub Has 92 Data Sources (48 Are Currently Active) for This Company

= sources impacting the current ratings
= sources not impacting the current ratings, but included in earlier ratings for this company
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO

Original Data Values

(unsubscribed users can see the list, subscribers can see the data details for most sources)

Data source name

Data source element name Minimum value Value provided by datasource Maximum value Data description
Boston College Center for Corporate Citizenship (BCCCC)
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Brand Value / Enterprise Value (%) -48.164682123 0.0414 316.6056 NA
Brand Value 2012 581.1854 NA
BSI 50 63.6637 88.4717 NA
Domicile SWITZERLAND NA
Enterprise Value NA 23414.3951 NA NA
Reviewed ? YES NA
Sector Consumer, Non-cyclical NA
SUBSCRIPTION INFO
Brand Value 2013 11.095 2824.5039 67875.2014 NA
BSI 50 75.8659 89.6275 NA
Domicile SWITZERLAND NA
Sector Consumer, Non-cyclical NA
Reviewed LW NA
Brand Rating 2013 BBB AA+ AAA+ NA
Enterprise Value 2013 0 175976.5506 435750.9811
SUBSCRIPTION INFO
Brand Value / Enterprise Value (%) 0.009 0.016 1.07 NA
Brand Value 2014 10 2824.5039 87304 A brand strength is assessed by using our Brand Strength Index framework. This benchmarks the strength, risk and future potential of a brand relative to its competitors by assessing input measures, brand equity measures, and output performance across four
BSI 51.3 78.6151 94.2 NA
Domicile SWITZERLAND NA
Enterprise Value 2014 66 212262.8264 526619 NA
Sector Consumer, Non-cyclical NA
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
0. Further Information NA NA NA NA
0.1. Introduction - Please give a general description and introduction to your organization. NA The Novartis Mission: We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding perf NA NA
5.1e Identified climate change risks driven by changes in other climate-related developments? NA Yes NA NA
5.1f. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; (iii) the costs associated with these actions NA RO2: Reduction of biodiversity: (i) Potential financial implication: The potential size of this risk could be the current market size of products based on natural products or derivatives, currently more than USD 2 billion.(ii) Method to manage the risk: N NA NA
5.1g. Please explain why you do not consider your company to be exposed to risks driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
5.1h. Please explain why you do not consider your company to be exposed to risks driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
5.1i. Please explain why you do not consider your company to be exposed to risks driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
6. Attachments NA NA NA NA
6. Further Information NA NA NA NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Opportunities driven by changes in regulation; Opportunities driven by changes in physical climate parameters; Opportunities driven by changes in other climate-related developments NA NA
6.1a Identified climate change opportunities that are driven by changes in regulation? NA Yes NA NA
6.1b. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA OR2: Surplus EU-ETS allowances: (i) Potential financial implication: As in the first two Phases of EU-ETS Novartis could also be able to reduce its GHG performance in a way that it will result in surplus allowances that can be sold. Particularly in early NA NA
6.1c Identified climate change opportunities that are driven by changes in physical climate parameters? NA Yes NA NA
14. Attachments NA NA NA NA
6.1d. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA OP1 Spread of tropical diseases to temperate zones and related need for medication: (i) Potential financial implications: Increased need for medication against tropical diseases to highly populated and highly developed areas such as USA, Europe and North NA NA
6.1e Identified opportunities that are driven by changes in other climate-related developments? NA Yes NA NA
6.1f. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA OO1: reputation benefits from leading position in energy and climate performance: (i) Potential financial implication: The financial implication of this benefit is difficult to assess and an amount has not been determined by Novartis so far, due to too h NA NA
13. Attachments NA NA NA NA
11. Attachments NA NA NA NA
11. Further Information NA NA NA NA
11.1. Do you consider that the grid average factors used to report Scope 2 emissions in Question 8.3 reflect the contractual arrangements you have with electricity suppliers? NA Yes NA NA
11.1a. You may report a total contractual Scope 2 figure in response to this question. Please provide your total global contractual Scope 2 GHG emissions figure in metric tonnes CO2e 0 NA 17902000 NA
11.2. Has your organization retired any certificates, e.g. Renewable Energy Certificates, associated with zero or low carbon electricity within the reporting year or has this been done on your behalf? NA No NA NA
3.1e. Please explain (i) why not; and (ii) forecast how your emissions will change over the next five years NA NA NA NA
3.2. Does the use of your goods and/or services directly enable GHG emissions to be avoided by a third party? No No Yes NA
3.2a. Please provide details (see guidance) NA NA NA NA
3.3c Number of methods used to drive investment in emissions reduction activities. 0 3 12 NA
3.3c. What methods do you use to drive investment in emissions reduction activities? NA Lower return on investment (ROI) specification, Internal incentives/recognition programs, Other NA NA
5. Attachments NA NA NA NA
5. Further Information NA NA NA NA
5.1. Have you identified any climate change risks (current or future) that have potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Risks driven by changes in regulation; Risks driven by changes in physical climate parameters; Risks driven by changes in other climate-related developments NA NA
5.1a Identified risks driven by changes in regulation? NA NA NA NA
5.1b. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; and (iii) the costs associated with these actions NA RR1: EU-ETS:(i) In 2005 before EU-ETS started, Novartis estimated costs of lacking allowances of the sites included in the EU-ETS until 2012 to be approximately USD 5.5 million, related to a gap of 150kt at an expected price of Euro 25 per ton. As the wo NA NA
14. Further Information NA NA NA NA
1.1. Where is the highest level of direct responsibility for climate change within your company? No individual or committee with overall responsibility for climate change Individual/Sub-set of the Board or other committee appointed by the Board Individual/Sub-set of the Board or other committee appointed by the Board NA
1.1a. Please identify the position of the individual or name of the committee with this responsibility NA - Health, Safety Environment Steering Committee (HSE SteCom) chaired by the company CEO. The Novartis CEO, Joseph Jimenez, is the chairman of the Health, Safety & Environmental Steering Committee (HSE SteCom), which is responsible for authorising and spo NA NA
1.2. Do you provide incentives for the management of climate change issues, including the attainment of targets? No Yes Yes NA
13. Further Information NA NA NA NA
13.1. How do your absolute emissions (Scope 1 and 2 combined) for the reporting year compare to the previous year? Increased Increased Decreased NA
13.1a (i) If absolute emissions (Scope 1 and 2 combined) have increased, decreased or remained the same overall compared to the previous year, state direction of change NA Moderately Increased NA NA
13.1a (ii) If absolute emissions (Scope 1 and 2 combined) have increased, decreased or remained the same overall compared to the previous year, state the reason for the direction of change NA Increase: Emissions reduction activities, Decrease: Acquisitions NA NA
13.1a (iii) If emissions have increased, decreased or remained the same overall, provide the emissions value (%) NA Decrease: , Increase: , Emission value for which direction is not stated: NA NA
2012 Score 0 91 100 NA
2012 Performance Band E B A NA
2.3a. Please explain (i) the engagement process and (ii) actions you are advocating NA 1) World Business Council for Sustainable Development (WBCSD): (i) Engagement process: i. Method of engagement: Novartis primary method of engagement is being an active member of the WBCSD since its foundation in 1997, contributing to the workstreams of NA NA
8.8. Are carbon dioxide emissions from the combustion of biologically sequestered carbon (i.e. carbon dioxide emissions from burning biomass/biofuels) relevant to your company? No No Yes NA
8.8a. Please provide the emissions in metric tonnes CO2e 0.01 NA 27263000 NA
Management 4. Attachments NA https://www.cdproject.net/Sites/2012/24/13524/Investor CDP 2012/Shared Documents/Attachments/InvestorCDP2012/4.Communication/Novartis_Annual_Report_2011_p76.pdf NA NA
Management 4. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? NA 7 NA NA
5.1d. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; and (iii) the costs associated with these actions NA RP5: Availability of energy and water:(i) Potential financial implication: Novartis in 2011 had annual total cost for energy (fuels and electricity) of USD 421 million and for water (from own wells and purchased) of USD 58 million. We expect the costs fo NA NA
2. Attachments NA NA NA NA
2. Further Information NA NA NA NA
5.1c Identified climate change risks driven by change in physical climate parameters? NA Yes NA NA
2.1. Please select the option that best describes your risk management procedures with regard to climate change risks and opportunities NA Integrated into multi-disciplinary company wide risk management processes NA NA
2.1a. Please provide further details (see guidance) NA i) Scope of the Novartis risk management: Novartis manages risks proactively by implementing appropriate preventive and contingency measures. Risks include all climate change related potential risks and opportunities including natural disasters such as fl NA NA
2.2. Is climate change integrated into your business strategy? No Yes Yes NA
2.2a. Please describe the process and outcomes (see guidance) NA The Novartis business strategy is to develop and further strengthen a diverse healthcare portfolio, including pharmaceuticals, eye care products, generic medications, consumer health products, and vaccines and diagnostic tools. It is our belief that this NA NA
2.2b. Please explain why not NA NA NA NA
2.3. Do you engage with policy makers to encourage further action on mitigation and/or adaptation? No Yes Yes NA
3. Attachments NA NA NA NA
3. Further Information NA NA NA NA
3.1. Did you have an emissions reduction target that was active (ongoing or reached completion) in the reporting year? No Absolute target Absolute and intensity targets NA
14.1. Do you participate in any emission trading schemes? No, and we do not currently anticipate doing so in the next two years Yes Yes NA
14.2. Has your company originated any project-based carbon credits or purchased any within the reporting period? No No Yes NA
6.1g. Please explain why you do not consider your company to be exposed to opportunities driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
6.1h. Please explain why you do not consider your company to be exposed to opportunities driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
6.1i. Please explain why you do not consider your company to be exposed to opportunities driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
7. Attachments NA NA NA NA
7. Further Information NA NA NA NA
7.1. Please provide your base year and base year emissions (Scopes 1 and 2) NA NA NA NA
0.4. Currency selection Please select the currency in which you would like to submit your response. All financial information contained in the response should be in this currency. NA USD($) NA NA
1. Attachments NA NA NA NA
1. Further Information NA NA NA NA
8.7. Please indicate the verification/assurance status that applies to your Scope 2 emissions More than 0% but less than or equal to 20% NA More than 90% but less than or equal to 100% NA
11.1b. Explain the basis of the alternative figure (see guidance) NA NA
14.1b. What is your strategy for complying with the schemes in which you participate or anticipate participating? Novartis is in full compliance with EU-ETS requirements. It is the strategy to minimize emissions from these sites in order to remain below the amount of allowances being allocated. The strategy includes coordination between the seven sites being invo NA
8.1. Please select the boundary you are using for your Scope 1 and 2 greenhouse gas inventory NA NA NA NA
8.2a. Please provide your gross global Scope 1 emissions figure in metric tonnes CO2e 92 NA 231902967 NA
8.3a. Please provide your gross global Scope 2 emissions figure in metric tonnes CO2e 293 NA 8071070 NA
8.4. Are there are any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1 and Scope 2 emissions which are not included in your disclosure? NA No NA NA
8.6. Please indicate the verification/assurance status that applies to your Scope 1 emissions More than 0% but less than or equal to 20% NA More than 90% but less than or equal to 100% NA
SUBSCRIPTION INFO
8.7. Please indicate the verification/assurance status that applies to your Scope 2 emissions Third party verification or assurance complete Proportion of Scope 2 emissions that are verified/assured for 2011-2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.7a. Please indicate the proportion of your Scope 2 emissions that are verified/assured More than 0% but less than or equal to 20% More than 90% but less than or equal to 100% More than 90% but less than or equal to 100%
8.7b Reporting Period From/To/Please provide further details of the verification/assurance undertaken, and attach the relevant statements/Type of verification or assurance/Relevant standard/Attach the document 1 Jan 2012/31 Dec 2012/Limited assurance/ISAE3000/https://www.cdproject.net/sites/2013/24/13524/Investor CDP 2013/Shared Documents/Attachments/Investor-8.7b-C3-RelevantStatement/Novartis_AR_CR_2012.pdf
8.8. Are carbon dioxide emissions from biologically sequestered carbon relevant to your organization? No
8.8a. Please provide the emissions in metric tonnes CO2 NA
8.8a. Please provide the emissions in metric tonnes CO2e 0.05 NA 13638000
9.1. Do you have Scope 1 emissions sources in more than one country? Yes
9.1a Reporting Period From/To/Please complete the table below: Country/Region/Scope 1 metric tonnes CO2e 1 Jan 2012/31 Dec 2012/United States of America/181228
9.2. Please indicate which other Scope 1 emissions breakdowns you are able to provide (tick all that apply) NA By business division; By GHG type; By activity NA
9.2a Reporting Period From/To/Please break down your total gross global Scope 1 emissions by business division: Business division/Scope 1 emissions (metric tonnes CO2e) 1 Jan 2012/31 Dec 2012/Pharmaceuticals/219805
9.2b Reporting Period From/To/Please break down your total gross global Scope 1 emissions by facility: Facility/Scope 1 emissions (metric tonnes CO2e) No Response
9.2c Reporting Period From/To/Please break down your total gross global Scope 1 emissions by GHG type: GHG type/Scope 1 emissions (metric tonnes CO2e) 1 Jan 2012/31 Dec 2012/CO2/628447
9.2d Reporting Period From/To/Please break down your total gross global Scope 1 emissions by activity: Activity/Scope 1 emissions (metric tonnes CO2e) 1 Jan 2012/31 Dec 2012/Manufacturing (onsite combustion & processes)/369913
9.2e Reporting Period From/To/Please break down your total gross global Scope 1 emissions by legal structure: Legal structure/Scope 1 emissions (metric tonnes CO2e) No Response
0.3. Country list configuration Brazil
0.4. Currency selection Please select the currency in which you would like to submit your response. All financial information contained in the response should be in this currency. USD($)
0.4. Please select the currency in which you would like to submit your response. USD($)
0.5. Please select if you wish to complete a shorter information request. NA
0.6. Modules NA As part of the Investor CDP information request, electric utilities, companies with electric utility activities or assets, companies in the automobile or auto component manufacture sectors and companies in the oil and gas industry should complete suppleme
1. Attachments NA NA NA
1. Further Information NA NA NA
1.1. Where is the highest level of direct responsibility for climate change within your company? No individual or committee with overall responsibility for climate change Individual/Sub-set of the Board or other committee appointed by the Board Individual/Sub-set of the Board or other committee appointed by the Board
1.1a. Please identify the position of the individual or name of the committee with this responsibility NA - Health, Safety Environment Steering Committee (HSE SteCom) chaired by the company CEO. The Novartis CEO, Joseph Jimenez, is the chairman of the Health, Safety & Environmental Steering Committee (HSE SteCom), which is responsible for authorising and NA
1.2. Do you provide incentives for the management of climate change issues, including the attainment of targets? No Yes Yes
1.2a. Who is entitled to benefit from these incentives? Business unit managers/Monetary reward/Divisional managers are rewarded for meeting division specific absolute reduction targets on total Scope1 and Scope2 GHG (in tons CO2e), CO2 emissions from vehicles fleet (in tons CO2) and energy savings targets (sav
10.1. Do you have Scope 2 emissions sources in more than one country? Yes
10.1a Reporting Period: From/To/Please complete the table below: Country/Region/Scope 2 metric tonnes CO2e/Purchased and consumed electricity, heat, steam or cooling (MWh)/Purchased and consumed low carbon electricity, heat, steam or cooling (MWh) 1 Jan 2012/31 Dec 2012/United States of America/373635/698434/10221
10.2. Please indicate which other Scope 2 emissions breakdowns you are able to provide (tick all that apply) NA By business division; By activity NA
10.2a Reporting Period From/To/Please break down your total gross global Scope 2 emissions by business division: Business division/Scope 2 emissions (metric tonnes CO2e) 1 Jan 2012/31 Dec 2012/Sandoz/324211
10.2b Reporting Period From/To/Please break down your total gross global Scope 2 emissions by facility: Facility/Scope 2 emissions (metric tonnes CO2e) No Response
10.2c Reporting Period: From/To/Please break down your total gross global Scope 2 emissions by activity: Activity/Scope 2 emissions (metric tonnes CO2e) 1 Jan 2012/31 Dec 2012/Manufacturing/741406
10.2d Reporting Period: From/To/Please break down your total gross global Scope 2 emissions by legal structure: Legal structure/Scope 2 emissions (metric tonnes CO2e) No Response
11. Attachments NA NA NA
11. Further Information NA NA NA
11.1. What percentage of your total operational spend in the reporting year was on energy? More than 0% but less than or equal to 5% More than 0% but less than or equal to 5% More than 95% but less than or equal to 100%
11.2. Please state how much fuel, electricity, heat, steam, and cooling in MWh your organization has purchased and consumed during the reporting year: Energy type/MWh Fuel/2273628;Electricity/2415354;Heat/180963;Steam/557897;Cooling/0
11.3. Please complete the table by breaking down the total "Fuel" figure entered above by fuel type: Fuels/MWh Natural gas/2084771
11.4. Please provide details of the electricity, heat, steam or cooling amounts that were accounted at a low carbon emission factor: Basis for applying a low carbon emission factor/MWh associated with low carbon electricity, heat, steam or cooling Supplier specific, backed by instruments/183762
12. Attachments NA
12. Further Information NA
12.1. How do your absolute emissions (Scope 1 and 2 combined) for the reporting year compare to the previous year? Decreased
12.1a Reason of change Emissions reduction activities, Divestment, Acquisitions, Mergers, Change in output, Change in methodology, Change in boundary, Change in physical operating conditions, Unidentified, Other
12.1a. Reason: Emissions value (percentage) Emissions reduction activities: 3/Divestment: 0/Acquisitions: 0.38/Mergers: 0/Change in output: 0/Change in methodology: 0/Change in boundary: 0/Change in physical operating conditions: 0/Unidentified: 0/Other: 4
12.2. Please describe your gross combined Scope 1 and 2 emissions for the reporting year in metric tonnes CO2e per revenue: Intensity figure/Metric numerator/% change from previous year/Direction of change from previous year/Reason for change 0.029/metric tonnes CO2e/0/No change/Despite a 3% reduction in total Scope 1 & Scope 2 GHG emissions, intensity measured against sales remains unchange due to a 3% drop in sales between 2011 and 2012. The drop can be mainly attributed to currency fluc
12.3. Please describe your gross combined Scope 1 and 2 emissions for the reporting year in metric tonnes CO2e per FTE: Intensity figure/Metric numerator/% change from previous year/Direction of change from previous year/Reason for change 0.013/metric tonnes CO2e/8/Decrease/The number of Novartis' associates increased by 5% between 2011 and 2012 due to the organic growth within each division, while absolute GHG emissions declinded by 3%.
12.4. Please provide an additional intensity (normalized) metric that is appropriate to your business operations: Intensity figure/Metric numerator/% change from previous year/Direction of change from previous year/Reason for change 0.325/metric tonnes CO2e/6/Decrease/The gross floor area of Novartis operations increased by 3% due to expansion projects at various sites, while absolute GHG emissions declined by 3%.
13.1. Do you participate in any emissions trading schemes? Yes
13.1b. What is your strategy for complying with the schemes in which you participate or anticipate participating? Novartis is in full compliance with EU-ETS requirements. It is the strategy to minimize emissions from these sites in order to remain below the amount of allowances being allocated. The strategy includes coordination between the seven sites being invo
13.2. Has your company originated any project-based carbon credits or purchased any within the reporting period? Yes
14. Attachments NA NA NA
14. Further Information NA NA NA
14.1. Do you participate in any emission trading schemes? No, and we do not currently anticipate doing so in the next two years Yes Yes
14.1b. What is your strategy for complying with the schemes in which you participate or anticipate participating? Novartis is in full compliance with EU-ETS requirements. It is the strategy to minimize emissions from these sites in order to remain below the amount of allowances being allocated. The strategy includes coordination between the seven sites being invo
14.2. Has your company originated any project-based carbon credits or purchased any within the reporting period? No Yes Yes
14.2. Please indicate the verification/assurance status that applies to your Scope 3 emissions No third party verification or assurance
14.2a. Please indicate the proportion of your Scope 3 emissions that are verified/assured NA
14.3. Are you able to compare your Scope 3 emissions for the reporting year with those for the previous year for any sources? Yes
14.4. Do you engage with any of the elements of your value chain on GHG emissions and climate change strategies? (Tick all that apply) Yes, our suppliers
14.4a. Please give details of methods of engagement, your strategy for prioritizing engagements and measures of success Novartis has begun to engage with suppliers of packaging materials within the framework of the Novartis Sustainable Packaging initiative. We have asked several suppliers to provide carbon footprint data on their products and are looking at selecting less
14.4d. Please explain why not and any plans you have to develop an engagement strategy in the future NA
2. Attachments NA NA NA
2. Further Information NA NA NA
2.1. Please select the option that best describes your risk management procedures with regard to climate change risks and opportunities NA Integrated into multi-disciplinary company wide risk management processes NA
2.1a. Please provide further details i) Scope of the Novartis risk management: Novartis manages risks proactively by implementing appropriate preventive and contingency measures. Risks include all climate change and environment-related potential risks and opportunities including natural disa
2.1a. Please provide further details (see guidance) NA i) Scope of the Novartis risk management: Novartis manages risks proactively by implementing appropriate preventive and contingency measures. Risks include all climate change and environment-related potential risks and opportunities including natural disa NA
2.2. Is climate change integrated into your business strategy? No Yes Yes
2.2a. Please describe the process and outcomes The Novartis business strategy is to develop and further strengthen a diverse healthcare portfolio, including pharmaceuticals, eye care products, generic medications, consumer health products, and vaccines & diagnostic tools. It is our belief that th
2.2a. Please describe the process and outcomes (see guidance) NA The Novartis business strategy is to develop and further strengthen a diverse healthcare portfolio, including pharmaceuticals, eye care products, generic medications, consumer health products, and vaccines & diagnostic tools. It is our belief that th NA
2.2b. Please explain why not NA NA NA
2.3. Do you engage in activities that could either directly or indirectly influence policy on climate change through any of the following? (tick all that apply) Yes
2.3. Do you engage with policy makers to encourage further action on mitigation and/or adaptation? No No Yes
2.3a. On what issues have you been engaging directly?: Focus of legislation/Corporate Position/Details of engagement/Proposed solution NA
2.3a. Please explain (i) the engagement process and (ii) actions you are advocating NA NA NA
2.3b. Are you on the Board of any trade associations or provide funding beyond membership? No
2.3c. Please enter the details of those trade associations that are likely to take a position on climate change legislation/Trade association NA
2.3d. Do you publically disclose a list of all the research organizations that you fund? NA
2.3e. Do you fund any research organizations to produce public work on climate change? NA
2.3f. Please describe the work and how it aligns with your own strategy on climate change NA
2.3g. Please provide details of the other engagement activities that you undertake 1) World Business Council for Sustainable Development (WBCSD): (i) Engagement process: i. Method of engagement: Novartis primary method of engagement is being an active member of the WBCSD since its foundation in 1997, contributing to the work streams of
2.3h. What processes do you have in place to ensure that all of your direct and indirect activities that influence policy are consistent with your overall climate change strategy? Active members and participants in the WBCSD and UN-GC activities are members of either top management or corporate functional managers of the Company: WBCSD: The CDO is Council member to the WBCSD, the global head HSE&BC is liaison delegate to the W
2.3i. Please explain why you do not engage with policy makers NA
3. Attachments NA NA NA
3. Further Information NA NA NA
3.1. Did you have an emissions reduction target that was active (ongoing or reached completion) in the reporting year? No Absolute target Absolute and intensity targets
3.1a. Absolute target/ID/Scope/% of emissions in scope/% reduction from base year/Base year/Base year emissions (metric tonnes CO2e)/Target year/Comment 1/Other: Scope 1 vehicle emissions/100/20/2010/216200/2015/The previous target for scope 1 GHG emissions from vehicles was over-achieved in 2010 with a total reduction of 16% since 2005. Reductions are achieved by the use of more fuel efficient vehicles t
3.1b. Intensity target/ID/Scope/% of emissions in scope/% reduction from base year/Metric/Base year/Normalized base year emissions/Target year/Comment No Response
3.1c. What change in absolute emissions this intensity target reflects/ID/Direction of change anticipated in absolute Scope 1+2 emissions at target completion?/% change anticipated in absolute Scope 1+2 emissions No Response
3.1d. Please provide details on your progress against this target made in the reporting year/ID/% complete (time)/% complete (emissions)/Comment 1/60/94/Novartis issued a target to reduce GHG emissions from vehicles by 20% by 2015 based on the 2010 baseline. A reduction of 18.9% has already been achieved by the end of 2012.
3.1e. Please explain (i) why not; and (ii) forecast how your emissions will change over the next five years NA NA NA
3.2. Does the use of your goods and/or services directly enable GHG emissions to be avoided by a third party? No No Yes
3.2a. Please provide details (see guidance) NA NA NA
3.3. Did you have emissions reduction initiatives that were active within the reporting year (this can include those in the planning and/or implementation phases) No Yes Yes
3.3a. Please identify the total number of projects at each stage of development, and for those in theimplementation stages, the estimated CO2e savings/Stage of development/3.3a. Number of projects/Total estimated annual CO2e savings in metric tonnes CO2e Under investigation/14/
3.3c Number of methods used to drive investment in emissions reduction activities. 0 3 13 Number of methods used to drive investment in emissions reduction activities.
3.3c. What methods do you use to drive investment in emissions reduction activities? NA Lower return on investment (ROI) specification, Internal incentives/recognition programs, Other NA
3.3c. What methods do you use to drive investment in emissions reduction activities?/Comment Lower return on investment (ROI) specification/We allow a relaxed payback scheme (over the full lifetime of the asset) for energy projects and require that all relevant investment projects include an energy challenge.
4. Attachments NA
4. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? - Further Information NA
4.1. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? 7 The number of corporate annual reports and voluntary publications (complete and/or underway) made about the company’s response to climate change and GHG emissions performance
5. Attachments NA NA NA
5. Further Information NA NA NA
5.1. Have you identified any climate change risks (current or future) that have potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Risks driven by changes in regulation; Risks driven by changes in physical climate parameters; Risks driven by changes in other climate-related developments NA
5.1a. Climate change risks driven by changes in regulation Yes
5.1a. Please describe your risks driven by changes in regulation /ID/Risk driver/ Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact RR1/Cap and trade schemes/EU-ETS: Novartis has 7 sites in the European Union that are part of the European Emissions Trading Scheme (EU-ETS). The total amount of allowances annually for the second Period (NAP II) is 200,885 tons. With an average price of
5.1b. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk and (iii) the costs associated with these actions RR1: EU-ETS:(i) In 2005 before EU-ETS started, Novartis estimated costs of lacking allowances of the sites included in the EU-ETS until 2012 to be approximately USD 5.5 million, related to a gap of 150kt at an expected price of Euro 25 per ton. As the wo
5.1c. Climate change risks driven by change in physical climate parameters Yes
5.1c. Please describe your risks that are driven by change in physical climate parameters/ID/Risk driver/Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact RP1/Snow and ice/Melting of glaciers and related changes in water availability or temporary water scarcity: Novartis has several locations north and south of the Alps in Kundl, Austria, Menges and Lendava, Slovenia and Rovereto, Italy, with fermentation
5.1d. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; and (iii) the costs associated with these actions NA RP5: Availability of energy and water:(i) Potential financial implication: Novartis in 2012 had annual total cost for energy (fuels and electricity) of USD 420 million and for water (from own wells and purchased) of USD 34 million. We expect the costs fo NA
5.1e. Please describe your risks that are driven by changes in other climate-related developments/ID/Risk driver/Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact 5-A/Uncertainty of physical risks/As a food company dependent on agriculturally based ingredients, we believe that climate change poses a risk to our supply chain. As average temperatures increase, rainfall and snowfall come at uncertain times and climate
5.1e.Climate change risks driven by changes in other climate-related developments Yes
5.1f. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; (iii) the costs associated with these actions NA RO2: Reduction of biodiversity: (i) Potential financial implication: The potential size of this risk could be the current market size of products based on natural products or derivatives, currently more than USD 2 billion.(ii) Method to manage the risk: N NA
5.1g. Please explain why you do not consider your company to be exposed to risks driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
5.1h. Please explain why you do not consider your company to be exposed to risks driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
5.1i. Please explain why you do not consider your company to be exposed to risks driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
6. Attachments NA NA NA
6. Further Information NA NA NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Opportunities driven by changes in regulation; Opportunities driven by changes in physical climate parameters; Opportunities driven by changes in other climate-related developments NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? -Transparency Yes
6.1a Identified climate change opportunities that are driven by changes in regulation? NA Yes NA
6.1a. Please describe your opportunities that are driven by changes in regulation/ID/Opportunity driver/Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact OR1/International agreements/Clear regulation resulting in high value of carbon offsets: An agreement on climate change targets at international negotiations in the coming years will help Novartis in setting its own GHG emission reduction targets that are
6.1b. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity and (iii) the costs associated with these actions OR2: Surplus EU-ETS allowances: (i) Potential financial implication: As in the first two Phases of EU-ETS Novartis could also be able to reduce its GHG performance in a way that it will result in surplus allowances that can be sold. Particularly in early
6.1c. Please describe the opportunities that are driven by changes in physical climate parameters Yes
6.1d. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity and (iii) the costs associated with these actions OP1 Spread of tropical diseases to temperate zones and related need for medication: (i) Potential financial implications: Increased need for medication against tropical diseases to highly populated and highly developed areas such as USA, Europe and North
6.1e. Please describe the opportunities that are driven by changes in other climate-related developments Yes
6.1f. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA OO1: reputation benefits from leading position in energy and climate performance: (i) Potential financial implication: The financial implication of this benefit is difficult to assess and an amount has not been determined by Novartis so far, due to too h NA
6.1g. Please explain why you do not consider your company to be exposed to opportunities driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
6.1h. Please explain why you do not consider your company to be exposed to opportunities driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
6.1i. Please explain why you do not consider your company to be exposed to opportunities driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
7. Attachments NA NA NA
7. Further Information NA NA NA
7.1. Please provide your base year and base year emissions (Scopes 1 and 2)/7.1. Base year From Date:/To Date:/ Scope 1 Base year emissions (metric tonnes CO2e)/N39Scope 2 Base year emissions (metric tonnes CO2e) 2008-01-01/2008-12-31/696969/1074870
7.2. Please give the name of the standard, protocol or methodology you have used to collect activity data and calculate Scope 1 and Scope 2 emissions NA The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition) NA
7.3. Please give the source for the global warming potentials you have used Gas/Reference CO2/IPCC Fourth Assessment Report (AR4 - 100 year)
7.4. Please give the emissions factors you have applied and their origin; alternatively, please attach an Excel spreadsheet with this data Fuel/Material/Energy/Emission Factor/Unit/Reference Natural gas/55/Other: metric tonnes CO2e per TJ/International Energy Agency
8.1. Please select the boundary you are using for your Scope 1 and 2 greenhouse gas inventory NA Operational control NA Boundary used for Scope 1 and 2 greenhouse gas inventory during 2011-2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.2. Please provide your gross global Scope 1 emissions figure in metric tonnes CO2e NA Gross global Scope 1 emissions figure in metric tonnes CO2e for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.2. Please provide your gross global Scope 1 emissions figures in metric tonnes CO2e 637838
8.3. Please provide your gross global Scope 2 emissions figures in metric tonnes CO2e NA
8.4. Are there are any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1 and Scope 2 emissions which are not included in your disclosure? NA No NA Proportion of Scope 1 emissions that are verified/assured for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.4a Reporting Period From/To/Source/Scope/Explain why the source is excluded No Response
8.5 Reporting Period From/To/Please estimate the uncertainty of the total gross global Scope 1 and 2 emissions figures that you have supplied and specify the sources of uncertainty in your data gathering, handling and calculations/Scope 1 emissions No Response
8.6. Please indicate the verification/assurance status that applies to your Scope 1 emissions Third party verification or assurance complete Proportion of Scope 1 emissions that are verified/assured for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.6a. Please indicate the proportion of your Scope 1 emissions that are verified/assured More than 0% but less than or equal to 20% More than 90% but less than or equal to 100% More than 90% but less than or equal to 100%
8.6b Reporting Period From/To/Please provide further details of the verification/assurance undertaken, and attach the relevant statements: Type of verification or assurance/Attach the document 1 Jan 2012/31 Dec 2012/Limited assurance/ISAE3000/https://www.cdproject.net/sites/2013/24/13524/Investor CDP 2013/Shared Documents/Attachments/Investor-8.6b-C3-RelevantStatement/Novartis_AR_CR_2012.pdf
2013 Performance Band E B A NA
2013 Score 0 96 100 NA
0. Attachments NA NA NA If you have not been presented with a sector module that you consider would be appropriate for your company to answer, please select the module below. If you wish to view the questions first, please see https://www.cdproject.net/en-US/Programmes/Pages/Mor
0. Further Information NA NA NA If you are in these sectors (according to the Global Industry Classification Standard (GICS)), the corresponding sector modules will be marked as default options to your information request. If you want to query your classification, please email respond@c
0.1. Introduction - Please give a general description and introduction to your organization. NA The Novartis Mission: We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding perf NA
0.1. Please give a general description and introduction to your organization. The Novartis Mission: We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want to provide a shareholder return that reflects outstanding perf
0.2. Please state the start and end date of the year for which you are reporting data. 2012-01-01
CDP Water Data 2012
SUBSCRIPTION INFO
2.1. Are you able to identify which of your operations are located in water-stressed regions? No Response 4 answers 4 answers NA
0.4. Exclusions Are there any geographies, activities, facilities or types of water inputs/outputs within this boundary which are not included in your disclosure? NA No NA NA
2.2b. You may explain here why you are not able to identify which of your operations are located in regions subject to water stress or water-related risk and whether you have plans to explore this issue in the future No Response 3 answers 3 answers NA
0.4aList of Exclusions & Reason for Exclusions-Transparency & Reporting No Response No Response Answered NA
1.1. Does your company have a water policy, strategy or management plan? No Yes Yes NA
2.1bPlease list the water-stressed regions where you have operations and the percentage of your total operations in that area NA India/Mainly Mumbai Region/1 – 10Egypt/Nile River/1 – 10Singapore/Tuas Industrial Area/1 – 10Pakistan/Indus River/1 – 10Poland/Warsaw Area/1 – 10South Africa/Johannesburg Area/1 – 10 NA NA
2.1bPlease list the water-stressed regions where you have operations and the percentage of your total operations in that area-Transparency & Reporting No Response 4 answers 4 answers NA
2.2. Do you use other indicators (besides water stress) to identify operations which are located in regions subject to water-related risk? NA NA NA NA
0.1. Introduction Please give a general description and introduction to your organization. NA The Novartis Mission: We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. NA NA
0.2. Reporng Year Please state the start and end date of the year for which you are reporting data. 2.0. Enter the period that will be disclosed. NA 01-01-2011 - 31-12-2011 NA NA
0.3. Reporting Boundary Please indicate the category that describes the company, entities, or group for which you are reporting. NA Companies, entities or groups over which operational control is exercised. NA NA
2.3. Please specify the total percentage of your operations that are located in the regions at risk which you identified in questions 2.1 and/or 2.2 NA Yes NA NA
2.4. Please specify the basis you use to calculate the percentages used for questions 2.1 and/or 2.2 NA WBCSD NA NA
1.1a. Please describe your policy, strategy or plan, including the highest level of responsibility for it within your company and its geographical reach-Transaprency & Reporting Australia/CCA's Water Policy covers all aspects of water related operations activities from both municipal and groundwater sources across the beverage and food businesses. Global/The efficient management of water resources is an integral component of the Novartis Corporate Citizenship Policy: Novartis strives to make efficient use of natural resources and to minimize the environmental impacts of its activities and products United States of America/We have a philosophy to limit water waste and a strategy to identify reduction opportunities from development through operations through supply chain. We build our stores to green building standards (LEED and Green Globes), and e NA
1.1b. Does the policy, strategy or plan specify water reduction, quality or efficiency targets or other water-related goals? NA Global NA NA
1.1bDoes the water policy, strategy or plan specify water-related targets or goals? No Yes Yes NA
0.4aList of Exclusions & Reason for Exclusions NA NA NA NA
SUBSCRIPTION INFO
0.2. Reporting Year 2012-01-01
0.3. Reporting Boundary Companies, entities or groups over which operational control is exercised
0.4. Are there any geographies, activities, facilities or types of water inputs/outputs within this boundary which are not included in your disclosure? No
0.4a. List of Exclusions & Reason for Exclusions-Transparency & Reporting NA
0.4a. List of Exclusions & Reason for Exclusions-Transparency & Reporting (value) NA
1.1. Does your company have a water policy, strategy or management plan? No Yes Yes
1.1a. Please describe your policy, strategy or plan, including the highest level of responsibility for it within your company and its geographical reach-Transaprency & Reporting Australia/CCA's Water Policy covers all aspects of water related operations activities from both municipal and groundwater sources across the beverage and food businesses. NA United States of America/We have a philosophy to limit water waste and a strategy to identify reduction opportunities from development through operations through supply chain. We build our stores to green building standards (LEED and Green Globes), and e
1.1a. Please describe your policy, strategy or plan, including the highest level of responsibility for it within your company and its geographical reach-Transaprency & Reporting (value) NA
1.1b. Does the water policy, strategy or plan specify water-related targets or goals? Yes
1.1c. Description of Target/goal, its type and geographical reach -Transparency & Reporting 2 answers
1.1c. Description of Target/goal, its type and geographical reach -Transparency & Reporting (value) #NAME?
1.1d. You may explain here why your company does not have a water policy, strategy or plan and if you intend to put one in place. NA
1.2. What specific actions has your company taken to manage water resources or engage stakeholders in water-related issues and what are their outcomes?-Transparency & Reporting 2 answers
1.2. What specific actions has your company taken to manage water resources or engage stakeholders in water-related issues and what are their outcomes?-Transparency & Reporting (value) #NAME?
2.1. Are any of your operations located in water-stressed regions? Yes
2.1a. Please specify the method(s) you use to characterize water-stressed regions- Environmental policy & Reporting WBCSD
2.1a. Please specify the method(s) you use to characterize water-stressed regions- Environmental policy & Reporting (value) #NAME?
2.1b. Please list the water-stressed regions where you have operations and the percentage of your total operations in that area-Transparency & Reporting 1 answers
2.1b. Please list the water-stressed regions where you have operations and the percentage of your total operations in that area-Transparency & Reporting (value) #NAME?
2.2. Are there other indicators (besides water stress) which you wish to report that help you to identify which of your operations are located in regions subject to water-related risk? No
2.2a. Please list the relevant risk indicator of your total operations in that area-Environment Policy and Reporting NA
2.2b. You may explain here why you do not wish to report or why you do not use other indicators to identify which of your operations are located in regions subject to water-related risk. We do not use any additional indicators on a global level to assess or monitor water-related risk, however, the annual risk assessment undertaken by all Novartis sites would ensure that any significant water-related risks are incorporate into the site's r
2.3. Please specify the total proportion of your operations that are located in the regions at risk which you identified in questions 2.1 and/or 2.2. 0 1.6 99
2.4. The basis to use to calculate the percentages used for questions 2.1 and/or 2.2 2 answers
2.4. The basis to use to calculate the percentages used for questions 2.1 and/or 2.3 (value) #NAME?
2.5. Do any of your key inputs or raw materials (excluding water) come from regions subject to water-related risk? No
2.5a. Please state or estimate the percentage of your key water-intensive inputs (excluding water) that come from these regions-Transparency & Reporting NA
2.5b. You may explain here why you are not able to identify if any of your key inputs or raw materials come from regions subject to water-related risk and whether you have plans to explore this issue in the future. NA
3.1. Is your company exposed to water-related risks (current or future) that have the potential to generate a substantive change in your business operation, revenue or expenditure? Yes
3.1a. Please describe the current and/or future risks to your operations, the ways in which these risks affect or could affect your operations and your current or proposed strategies for managing them-Transparency & Reporting NA
3.1a. Please describe the current and/or future risks to your operations, the ways in which these risks affect or could affect your operations and your current or proposed strategies for managing them-Transparency & Reporting (value) #NAME?
3.1b. Please explain why you do not consider your company to be exposed to any water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure. NA
3.1c. Please explain why you do not know if your company is exposed to any water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure, and your plans to assess this risk in the future. NA
3.2. Country or geographical scale-Environment Policy & Reporting NA
3.2. What methodology do you use to analyze water-related risk across your operations?-Transparency & Reporting No Response
3.2. What methodology do you use to analyze water-related risk across your operations? NA
3.3. Do you require your key suppliers to report on their water use, risks and management? No
3.4. Is your supply chain exposed to water-related risks (current or future) that have the potential to generate a substantive change in your business operation, revenue or expenditure? Don't know
3.4b. Please explain why you do not consider your supply chain to be exposed to any water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure. NA
3.4c. Please explain why you do not know if your supply chain is exposed to water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure, and your plans to assess this risk in the future. At present Novartis does not identify water-intensive inputs from water-stressed regions in our supply chain due to the complexities involved in obtaining relevant water data from over 10,000 suppliers worldwide. While the resources for such a massive und
4.1. Has your business experienced any detrimental impacts related to water in the past five years? No
4.1. Please describe any detrimental impacts to business related to water your company has faced in the past five years, their financial impacts and whether they have resulted in any changes to company practices- Transparency & Reporting Answered
5.1. Do water-related issues present opportunities (current or future) that have the potential to generate a substantive change in your business operation, revenue or expenditure? Yes
5.1a. Please describe the current and/or future opportunities, the ways in which these opportunities affect or could affect your operations and your current or proposed strategies for exploiting them-Environmental Policy & Reporting 3 answers
5.1a. Please describe the current and/or future opportunities, the ways in which these opportunities affect or could affect your operations and your current or proposed strategies for exploiting them-Environmental Policy & Reporting (value) #NAME?
5.1b. Please explain why you do not consider water-related issues to present opportunities to your company that have the potential to generate a substantive change in your business operation, revenue or expenditure or supply chain. NA
5.1c. Please explain why you do not know whether water-related issues present opportunities to your company that have the potential to generate a substantive change in your business operation, revenue or expenditure. NA
6.1. Has your company identified any linkages or trade-offs between water and carbon emissions in its operations or supply chain? Yes
6.1a. Please describe the linkages or trade-offs between water and carbon emissions in its operations or supply chain?--Transparency & Reporting 2 answers
6.1a. Please describe the linkages or trade-offs and the related management policy or action between water and carbon emissions in its operations or supply chain?-Transparency & Reporting (value) #NAME?
7.1. Are you able to provide data, whether measured or estimated, on water withdrawals within your operations? Yes
7.1a. Please report the water withdrawals within your operations for the reporting year-Transparency & Reporting 0
7.1a. Please report the water withdrawals within your operations for the reporting year-Transparency & Reporting (value) 0
7.1b. Please explain why you are not able to provide data for water withdrawals. NA
7.2. Are you able to provide data, whether measured or estimated, on water recycling/reuse within your operations? Yes
7.2a. Please report the water recycling/reuse within your operations for the reporting year-Transparency & Reporting 3 answers
7.2a. Please report the water recycling/reuse within your operations for the reporting year-Transparency & Reporting (value) #NAME?
7.2b. Please explain why you are not able to provide data for water recycling/reuse within your operations. NA
7.2b. Please explain why you are not able to provide data for water recycling/reuse within your operations-Transparency & Reporting No Response
7.3. Please use this space to describe the methodologies used for questions 7.1 and 7.2 or to report withdrawals or recycling/reuse in a different format to that set out above. Each of the 283 reporting sites report water usage on a quarterly basis, and water input and output on a yearly basis. Automatic plausibility checks in the Novartis HSE Data Management System compare historical data already reported by the site to ensure
7.3. Please use this space to describe the methodologies used for questions 7.1 and 7.2 or to report withdrawals or recycling/reuse in a different format to that set out above-Transparency & Reporting Answered
7.4. Are any water sources significantly affected by your company's withdrawal of water? No
7.4a. Please list any water sources significantly affected by your company's withdrawal of water. NA
7.4b. You may explain here why your company's withrawal of water does not significantly affect any water sources. As a pharmaceutical company, Novartis operations are not water intensive. Only sites involved in fermentation processes use large volumes of water for cooling. These sites are located in areas of water abundance in Germany and Austria, and return water un
7.4b. You may explain here why your company's withrawal of water does not significantly affect any water sources-Transparency & reporting Answered
7.4c. Please explain why you do not know if any water sources are significantly affected by your company's withdrawal of water. NA
8.1. Are you able to identify discharges of water from your operations by destination, by treatment method and by quantity and quality using standard effluent parameters? Yes
8.1a. Please explain why you are not able to identify discharges from your operations by destination, treatment method , quantity and quality, and whether you have any plans to put in place systems that would enable you to do so. NA NA
8.2. Did your company pay any penalties or fines for significant breaches of discharge agreements or regulations in the reporting period? Yes NA
8.2a. Please describe the quality, quantity and destination of the water that was the subject of the significant breach(es), the associated fines and any actions taken to minimise the risk of future non-compliance #NAME? NA
8.3. Are any water bodies and related habitats significantly affected by discharges of water or runoff from your operations? No NA
8.3a. Please list any water bodies and related habitats which are significantly affected by discharge of water or runoff from your operations NA NA
8.3b. You may explain here why your company's discharge of water does not significantly affect any water bodies or associated habitats. Novartis has state-of-the-art internal waste water treatment plants operating in all facilities involved in chemical production and many sites involved in pharmaceutical production to ensure that emissions to water are kept to a minimum. Only non-contamin NA
8.3b. You may explain here why your company's discharge of water does not significantly affect any water bodies or related habitats-Tansparency & Reporting Answered NA
8.3c. Please explain why you do not know if any water bodies and associated habitats are significantly affected by discharge of water or runoff from your operations. NA NA
9.1. Please provide any available financial intensity values for your company's water use across its operations 3 answers NA
9.1. Please provide any available financial intensity values for your company's water use across its operations (value) #NAME? NA
9.2. Please provide any available water intensity values for your company's products or services across its operations. #NAME? NA
Please enter the name of the individual that has signed off (approved) the response and their job title Markus Lehni, Corporate Environment & Energy Manager Scott Hemphill Coporate Health, Safety & Environment Data Manager NA
SUBSCRIPTION INFO
2014 CEI Rating 100 NA
Firm-wide Organizational Competency Programs (10 points) Yes Yes NA
Fortune 1000 850 NA 1 NA
Has Employer-Supported Employee Resource Group OR Firm-Wide Diversity Council (10 points) Yes Yes NA
Has Parity Across Other “Soft” Benefits for Partners (10 points) Yes Yes NA
Headquarters Location East Hanover, NJ NA
Offers Partner Health/Medical Insurance (15 points) Yes Yes NA
Offers Transgender-Inclusive Health Insurance Coverage (10 points) Yes Yes NA
Positively Engages the External LGBT Community (15 points) Yes Yes NA
Prohibits Discrimination Based on Gender Identity or Expression (15 points) Yes Yes NA
Prohibits Discrimination Based on Sexual Orientation (15 points) Yes Yes NA
Responsible Citizenship Employers will have 25 points deducted from their score for a large-scale official or public anti-LGBT blemish on their recent records (-25 points) NA Yes NA
SUBSCRIPTION INFO
Type of Member Company
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Reduce 0 36 52 NA
Report 0 10 12 NA
Review 0 19 27 NA
SUBSCRIPTION INFO
Rank by Context-Based Score (1 to 100) 100 18 1 Climate counts rank
Sustainable N Y Y If a company has a score of less than or equal to one (?1), it is considered “sustainable”, whereas a company with a score greater than one (>1) is considered “unsustainable”
SUBSCRIPTION INFO
2011 Electricity Usage /MWh 35 2404563 272242310 Annual electricity consumption resulting from all operations within the defined boundaries of a given organisation.
2011 Renewables Usage /MWh 5 231873 20498400 Total number of MWh of electricity or proxy purchased globally from renewable energy power-generating projects directly or indirectly.
Biomass/Biofuel (%) 0 23 100 Biomass = woody waste; agricultural crops or waste; animal and other organic waste; energy crops; co-firing of biomass in fossil fuel generation plants. Biofuel = biofuels such as bioethanol and biodiesel.
Blend (%) 0 76 100 Blend = renewable electricity consisting of a mix of renewables as provided by for example third-party marketers.
Country Switzerland NA
Geothermal (%) 0 0 79 Geothermal = all electricity from geothermal facilities.
Global CREX rank 1 188 280 The CREX participants are ranked based on the percentage of renewable electricity procured for their own use in 2011, calculated by dividing renewable electricity consumption by total electricity consumption for the period.
Hydro (%) 0 0 100 Hydro = hydro projects from new generation capacity.
Sector Health Care NA ICB system top-level industry designation (via the Bloomberg Terminal).
Solar (%) 0 1 100 Solar = all electricity produced solar photovoltaics (PV) and solar thermal facilities.
Unknown (%) 0 0 100
Waste to energy (%) 0 0 100 Waste-to-energy = electricity using landfill gas or waste from other facilities such as wastewater treatment stations.
Wind (%) 0 0 100 Wind = all electricity from wind turbines.
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Reported Scope 3 Total (tCO2e) 670000000 - 0 Indicated the total reported Scope 3 (all other indirect emissions) of the company in metric tonnes of CO2 equivalent (tCO2e) as defined by the Greenhouse Gas Protocol. Where no Scope 3 emissions are reported, this is recorded as "No Data"
Scope 1+2 Intensity 11162.43 25.9 0.3 Intensity is calculated by adding together a company's Scope 1 and Scope 2 emissions and dividing by its turnover.
Global 800 Carbon Rank 800 29 1 Carbon Ranking of 800 international companies. Ranking is determined by EIO Methodology. See Source Info sheet for comments on it
No. of Scope 3 Categories Reported 1 - 15 This column indicates the number of Scope 3 Categories reported. Once placed into one of the four Disclosure Categories, companies are ranked by the number of Scope 3 categories disclosed.
Reported Scope 1+2 Total (tCO2e) 282000000 1459270 843 The total reported Scope 1 (all direct emissions) and Scope 2 (indirect electricity emissions) of the company in metric tonnes of CO2 equivalent (tCO2e) as defined by the Greenhouse Gas Protocol
Accepted or Inferred Scope 3 Intensity 8547.13 291.54 64.51 Unless the company reports all 15 Scope 3 categories as defined by the Greenhouse Gas Protocol Corporate Value Chain (Scope 3) Standard, an inferred figure based on the highest reported intensity for that sector, across the Global ET Universe, is shown
Category No Public Data Green Public, Complete, and Verified data Companies are placed into one of four data or 'disclosure' categories: 1) Public, Complete, and Verified data; 2) Public, Complete, and Unverified data; 3) Public, Incomplete, Verified or Unverified data; 4) No Public Data
Combined Scope 1+2+3 Intensity 12161.68 171.68 34.24 Combined Scope 1+2_3 Intensity is calculated by adding together a company's Scope 1 and Scope 2 emissions at 100% (disclosed or inferred) + 50% of Scope 3 emissions (disclosed or inferred).
Market Value ($Million) 1667.87 169848 358143.1 A company's market value, or market capitalism (number of shares times x share price). This value was taken on 23.08.2011
SUBSCRIPTION INFO
Sum of Biogenic CO2 emissions 2.9 NA 23623772.5 Total biogenic CO2 emissions.
Sum of CO2 emissions (non-biogenic) 0.3 99915.8 53858607.2 Total non-biogenic CO2 emissions
Sum of Gases with No Listed GWP (metric tons) 0.3397 NA 1036.4
Sum of HFC emissions 2558.79 NA 19215.8
Sum of HFE emissions NA NA
Sum of Methane (CH4) emissions 0.21 39.69 2491216.14 Total methane emissions
Sum of NF3 emissions 5332 NA 21231.68
Sum of Nitrous Oxide (N2O) emissions 0.31 58.59 10675387.54
Sum of PFC emissions 33930.1 NA 1221318.27
Sum of SF6 emissions 4254.2 NA 153581.4
Total reported direct emissions 30.03 100014.08 54200390.452 Total emissions of CO2 and other gases in metric tons.
Industry Description NA NA Description of the type of industry the facility serves.
Is Some CO2 captured on-site and therefore not emitted? N NA Y Indicates if all CO2 is emitted or if some is sequestered.
Number of reporting facilities 1 2 50 Number of facilities reported to the EPA.
Percentage of facilities that emit pollutants 2 50 100 Percent of reporting facilities that emit pollutants other than CO2.
Percentage of facilities that employ continuous emissions monitoring 6 NA 100
SUBSCRIPTION INFO
ceo:numberOfRatings 1 77 4026 The number of ratings of the CEO
ceo:pctApprove 0 86 100 Percent of ratings of the CEO that were approving
ceo:title NA The title of the company's CEO
employer:numberOfRatings 1 164 6549 The number of Glassdoor users who have rated this company as a place to work.
Glassdoor Employer Ratings 1 3.5 5 The Top Companies for Work-Life Balance list is based on employee feedback shared in company reviews on Glassdoor.
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Size NA MNE NA NA
Region NA Europe NA NA
Report Html Address NA http://www.novartis.com/corporate-responsibility/metrics-and-reporting/global-reporting-initiative.shtml NA NA
Report Pdf Address NA http://www.novartis.com/downloads/corporate-responsibility/metric-and-reporting/2011-GRI-report.pdf NA NA
Report reference IFC Performance Standards? NA No NA NA
Report reference ISO Standards? NA No NA NA
Report Title NA Novartis 2011 GRI report NA NA
Sector NA Healthcare Products NA NA
Sector Supplements (Final) NA Not Applicable NA NA
Application Level Undeclared A+ A+ G3 Application Levels indicate to which extent the GRI Guidelines have been utilized in the reporting and which set and number of disclosures have been addressed in the reporting. There are three Application Levels A, B and C.
Country (HQ) NA Switzerland NA NA
Date Added To Sr List NA April 3, 2013 NA NA
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Envtl. Mgmt. 28.6 84 91.9 Based on an analysis of companies tracked in Sustainalytics’ Global Platform, the Environmental Management Score is an assessment of how a company manages its environmental performance through policies, programs, targets, certifications, and the like. To
Green Score 0 74.3 100 NA
Rank 500 39 1 NA
Disclosure 0 81.9 100 Environmental disclosure was included as a stand-alone score to assess each company’s transparency with regard to its environmental performance. Specifically, this score evaluates the breadth and quality of company environmen
SUBSCRIPTION INFO
Carbon Productivity 0.015 0.384 0.963 GHG Productivity defined as Revenue ($US) / Total Greenhouse gas (GHG) Emissions (CO2e).
Energy Productivity 0.007 0.456 0.957 Energy Productivity defined as Revenue ($US) / Total Energy Consumption (GJ).
Newsweek Green Score 0.0 0.414 0.843 This score is derived from the following component scores: an Energy Productivity,Carbon Productivity, Water Productivity, Waste Productivity, Reputation, Pay Link, Sustainability Themed Committee, Audit ; weighted at 45 percent, 45 percent, and 10 percen
Pay Link No Yes Yes A mechanism to link the remuneration of any member of a company's senior executive team with the achievement of environmental performance targets.
Rank 500 220 1
Reputation 0.005 0.123 1 The Reputation score is made up of two components: (1) The RepRisk Index, which is a quantitative measure that captures criticism and quantifies a company exposure to ESG risks. (2) The second component is based on the number of environmental issues that
Sustainability Themed Committee No Yes Yes The existence of a committee at the Board of Directors level whose mandate is related to the sustainability of the company, including but not limited to environmental matters.
Waste Productivity 0.014 0.3 0.97 Waste Productivity is defined as Revenue ($US) / [Total waste generated (metric tonnes) – waste recycled/reused (metric tonnes)].
Water Productivity 0.012 0.124 0.992 Water Productivity is defined as Revenue ($US) / Total water use (m3).
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Corporate Governance 3 0.2 0 The scores for each ESG scope issue ranges from 0-3. The scoring refers to the number of times the company was criticized in relation to that scope issue: 0 = little or no exposure in the past 4 years; 1 = 5 direct relations in the past 4 years; 2 = 10 direct relations in the past 4 years; 3 = 20 direct relations in the past 4 years.
Current RRI 86 22 0 The RepRisk Index (RRI) is a quantitative risk measure that captures criticism and quantifies a company's exposure to controversial environmental, social and governance (ESG) issues. It does not measure a company's overall reputation, but rather is an indicator of their reputational risk.The Current RRI value indicates the current level of criticism about a company.
Employee Relations 3 0 0 The scores for each ESG scope issue ranges from 0-3. The scoring refers to the number of times the company was criticized in relation to that scope issue: 0 = little or no exposure in the past 4 years; 1 = 5 direct relations in the past 4 years; 2 = 10 direct relations in the past 4 years; 3 = 20 direct relations in the past 4 years.
Environmental FootPrint 3 0 0 The scores for each ESG scope issue ranges from 0-3. The scoring refers to the number of times the company was criticized in relation to that scope issue: 0 = little or no exposure in the past 4 years; 1 = 5 direct relations in the past 4 years; 2 = 10 direct relations in the past 4 years; 3 = 20 direct relations in the past 4 years.
SUBSCRIPTION INFO
Rank 400 66 1 REPORTWATCH RATING
Report Rating D B+ A REPORTWATCH RATING
SUBSCRIPTION INFO
Value of USG Contracts (in millions) 990 NA 1 Value of Iranian contracts.
Withdrawn NA Was the association with Iran withdrawn?
Nationality Switzerland Country the company is in.
On the list Yes Yes Is the company on the list.
SUBSCRIPTION INFO
SUBSCRIPTION INFO
include_measurement 0 1 1 Does your COP identify targets, define performance indicators and measure outcomes?
references_anti_corruption 0 1 1 Does your COP contain description of actions, and when relevant policies, related to anti-corruption?
references_environment 0 1 1 Does your COP contain description of actions, and when relevant policies, related to the environment?
references_human_rights 0 1 1 Does your COP contain description of actions, and when relevant policies, related to human rights?
references_labour 0 1 1 Does your COP contain description of actions, and when relevant policies, related to labour rights?
starts_on NA 06/01/2012 NA Start Date
differentiation NA advanced NA At what level is the declarer?
ends_on NA 06/01/2013 NA End Date
format NA standalone NA How is your COP shared with stakeholders?
SUBSCRIPTION INFO
ends_on NA 09/05/2014 NA End Date
format NA grace_letter NA How is your COP shared with stakeholders?
include_continued_support_statement 0 0 1 Does your COP contain a statement by the CEO (or equivalent) expressing continued support for the Global Compact and renewing your company’s ongoing commitment to the initiative and its principles?
include_measurement 0 1 1 Does your COP identify targets, define performance indicators and measure outcomes?
references_anti_corruption 0 0 1 Does your COP contain description of actions, and when relevant policies, related to anti-corruption?
references_environment 0 0 1 Does your COP contain description of actions, and when relevant policies, related to the environment?
references_human_rights 0 0 1 Does your COP contain description of actions, and when relevant policies, related to human rights?
references_labour 0 0 1 Does your COP contain description of actions, and when relevant policies, related to labour rights?
starts_on NA 06/07/2014 NA Start Date
World Business Council for Sustainable Development
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Strategic Partners Yes Yes Strategic Partners comprise some of the world’s leading corporate citizens and provide essential leadership in support of the Forum’s mission. Strategic Partners are a key force in our activities and communities at the global, regional and industry levels. They help shape our initiatives, projects and task forces and give intellectual guidance through the participation of their most senior executives on steering boards and in advisory groups. Their considerable financial support and in-kind services – including the provision of dedicated staff to assist with our operations – allow the Forum to deliver its programmes and advance worldwide economic and social progress.
SUBSCRIPTION INFO
Weighted score 1.2 4.1 5.9

Flags

(Other Indicators - things that don’t affect ratings but that help identify or classify companies)

SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
You have put report(s) in your cart
Go to my cart
Ok